← 產業報告目錄

Menopause Market Research Report by Treatment Type (Hormone Therapy, Non-Hormonal Treatment, Dietary Supplements), by Menopause Stage (Menopause, Perimenopause, Post-Menopause), by Application (Hot Flashes and Night Sweats (Vasomotor Symptoms), Vaginal Dryness and Atrophy, Sleep Disturbances, Mood Swings and Depression, Bone Health, Urinary Symptoms), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Channels), by Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) Forecast till 2035

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2026-05-02頁數 191報告編號 MRFRHC66570CR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

The global menopause market was valued at USD 17,628.21 million in 2025 and is projected to reach USD 30,415.70 million by 2035. The market is anticipated to expand at a CAGR of 5.7% during the forecast period, driven by rising awareness regarding women’s health and increasing demand for menopause management therapies. Rising Acceptance of Personalized Hormone Therapy One of the key reasons behind the strong growth of the menopause market is the widespread acceptance of personalized hormone therapy following recent clinical studies and updated medical guidelines. New technologies in hormones that are identical to those in the human body and delivery mechanisms through the skin are making more women consider these as the best long-term symptom treatment options. Key Segment Highlights By Treatment Type • Hormone Therapy – Effective therapies supporting widespread patient preference. • Non-Hormonal Treatment – Safer alternatives attracting broader consumer base. • Dietary Supplements – Herbal products gaining strong market visibility. By Menopause Stage • Menopause – Core treatment stage driving overall market growth. • Perimenopause – Preventive care demand steadily increasing among women. • Post-Menopause – Long-term wellness therapies witnessing higher adoption. By Application • Hot Flashes and Night Sweats – Leading application segment across menopause treatments. • Vaginal Dryness and Atrophy – Expanding awareness fueling product adoption rates. • Sleep Disturbances – Demand increasing for sleep improvement medications. • Mood Swings and Depression – Psychological care becoming integral to treatment. • Bone Health – Rising osteoporosis cases supporting treatment demand. • Urinary Symptoms – Improved diagnosis encouraging effective symptom management. By Distribution Channel • Hospital Pharmacy – Professional healthcare guidance driving consumer trust. • Retail Pharmacy – Broad availability supporting steady product sales. • Online Channels – Online healthcare platforms accelerating market penetration. North America is the leading menopause market worldwide mainly due to its mature healthcare system along with a high level of treatment awareness and strong patient involvement., whereas Europe is still going strong thanks to their well-organized public healthcare system. Meanwhile, Asia Pacific is emerging as the fastest-growing region driven by rising health consciousness and aging populations, with South America and the Middle East & Africa gradually expanding through improving healthcare access and awareness initiatives. Key Development: Astellas Pharma Inc. In December 2024, Astellas Pharma was approved by Health Canada to bring to the market the first-ever non-hormonal. treatment that directly addresses moderate to severe vasomotor symptoms commonly associated with menopause. Besides this approval, the drug was backed-up by the large-scale BRIGHT SKY Phase 3 clinical program that served as strong evidence of the drug effectiveness and showed that it was safe for long-term use, giving even more reason for the firm to bet on developing new menopause care solutions. Strategic Edge: Expansion of Non-Hormonal Therapies Introducing a highly effective non-hormonal treatment for vasomotor symptoms, Astellas Pharma's Veozah approval was a big step forward in the menopause market. The menopause market today is changing as treatment preferences are shifting, especially for women who want to try something other than the good old hormone therapies. Key Report Attributes • Market Size 2025: USD 17,628.21 Million • Market Size 2035: USD 30,415.70 Million • CAGR (2025-2035): 5.7% • Base Year: 2024 • Market Forecast Period: 2025-2035 Industry Segmentations Growth • By Treatment Type: Hormone Therapy - 4.8%, Non-Hormonal Treatment - 8.2%. • By Menopause Stage: Menopause - 5.4%, Perimenopause - 6.5%. • By Application: Hot Flashes and Night Sweats - 5.1%, Vaginal Dryness and Atrophy - 5.5%. • By Distribution Channel: Hospital Pharmacy - 4.8%, Retail Pharmacy - 5.8%.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ........................................... 20 2 MARKET INTRODUCTION ....................................... 22 2.1 DEFINITION ...................... 22 2.2 SCOPE OF THE STUDY ...... 22 2.3 RESEARCH OBJECTIVE ........... 22 2.4 MARKET STRUCTURE ........ 23 3 RESEARCH METHODOLOGY ................................. 24 3.1 OVERVIEW .......................... 24 3.2 DATA FLOW ........................ 26 3.2.1 DATA MINING PROCESS ...................................... 26 3.3 PURCHASED DATABASE: ........ 27 3.4 SECONDARY SOURCES: .......... 28 3.4.1 SECONDARY RESEARCH DATA FLOW: .................. 29 3.5 PRIMARY RESEARCH: ............ 30 3.5.1 PRIMARY RESEARCH DATA FLOW: ...................... 31 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ......................... 32 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ....... 32 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................ 33 3.6.1 REVENUE ANALYSIS APPROACH .......................... 33 3.7 DATA FORECASTING ............... 33 3.7.1 DATA FORECASTING TYPE ................................... 34 3.8 DATA MODELING .................. 35 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ................. 35 3.8.2 DATA MODELING: ..... 36 3.9 TEAMS AND ANALYST CONTRIBUTION ................................... 38 4 MARKET DYNAMICS ............................................... 40 4.1 INTRODUCTION ..................... 40 4.2 DRIVERS ............................. 41 4.2.1 EXPANDING ACCEPTANCE OF HORMONE THERAPY (HT) POST-WHI RE-EVALUATION .................................. 41 4.2.2 SHIFT TOWARDS NON-HORMONAL AND DIETARY SUPPLEMENTS .................... 41 4.2.3 GROWTH IN ONLINE CHANNELS & TELEHEALTH ............................................. 42 4.2.4 INNOVATION IN DELIVERY SYSTEMS.................... 42 4.3 RESTRAINTS ........................ 44 4.3.1 LIMITED EVIDENCE SUPPORTING SUPPLEMENTS ............................................ 44 4.3.2 CULTURAL STIGMA AND UNDERDIAGNOSIS ......... 44 4.3.3 HIGH COST OF NOVEL TREATMENTS ................... 45 4.4 OPPORTUNITIES ................... 47 4.4.1 DEVELOPMENT OF NON-HORMONAL THERAPIES ............................................ 47 4.4.2 FOCUS ON MENOPAUSE AT THE WORKPLACE ...... 47 5 MARKET DYNAMICS ............................................... 48 5.1 REGULATORY ENVIRONMENT & COMPLIANCE .......................... 48 5.2 TECHNOLOGICAL TRENDS & INNOVATION ............................... 49 5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ..................... 50 5.3.1 HOT FLASHES AND NIGHT SWEATS (VASOMOTOR SYMPTOMS) ...................... 50 5.3.2 VAGINAL DRYNESS AND ATROPHY ...................... 50 5.3.3 SLEEP DISTURBANCES ........................................ 50 5.3.4 MOOD SWINGS AND DEPRESSION ........................ 51 5.3.5 BONE HEALTH .......... 51 5.3.6 URINARY SYMPTOMS .......................................... 51 5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ................ 52 5.4.1 NORTH AMERICA ..... 52 5.4.2 EUROPE ................... 52 5.4.3 ASIA PACIFIC ........... 52 5.4.4 REST OF THE WORLD ........................................... 52 5.4.5 REIMBURSEMENT DYNAMICS .............................. 53 5.5 MARKET ENTRY & EXIT BARRIERS .......................................... 54 5.5.1 BARRIERS TO ENTRY ........................................... 54 5.5.2 BARRIERS TO EXIT ............................................... 54 5.6 PARTNERSHIPS & COLLABORATIONS ...................................... 55 5.7 CONSUMER & HEALTHCARE PROVIDER PREFERENCES ............... 56 5.7.1 CONSUMER PREFERENCES .................................. 56 5.7.2 HEALTHCARE PROVIDER PREFERENCES ............... 56 5.8 PESTLE ANALYSIS ............ 57 5.8.1 POLITICAL FACTORS ........................................... 57 5.8.2 ECONOMIC FACTORS .......................................... 57 5.8.3 SOCIAL FACTORS ..... 57 5.8.4 TECHNOLOGICAL FACTORS ................................. 57 5.8.5 LEGAL FACTORS ...... 58 5.8.6 ENVIRONMENTAL FACTORS ................................ 58 5.9 PORTER'S FIVE FORCES MODEL ........................................... 59 5.9.1 THREAT OF NEW ENTRANTS ................................ 60 5.9.2 BARGAINING POWER OF SUPPLIERS .................... 60 5.9.3 THREAT OF SUBSTITUTES ................................... 60 5.9.4 BARGAINING POWER OF BUYERS ......................... 60 5.9.5 INTENSITY OF RIVALRY ....................................... 60 5.10 PRODUCT PIPELINE ANALYSIS ............................................. 61 5.11 CASE STUDY ANALYSIS ......... 62 5.12 INVESTMENT & FUNDING SCENARIOS ................................... 63 5.13 POST-MARKET SURVEILLANCE & SAFETY DATA ........................ 64 5.14 DISEASE OVERVIEW .............. 65 5.15 DIAGNOSIS ......................... 66 5.16 CURRENT TREATMENT ..... 66 6 GLOBAL MENOPAUSE MARKET, BY TREATMENT ......................................... 68 6.1 OVERVIEW .......................... 68 7 GLOBAL MENOPAUSE MARKET, BY MENOPAUSE STAGE ........................... 71 7.1 OVERVIEW .......................... 71 8 GLOBAL MENOPAUSE MARKET, BY APPLICATION ....................................... 73 8.1 OVERVIEW .......................... 73 9 GLOBAL MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL ................... 76 9.1 OVERVIEW .......................... 76 10 GLOBAL MENOPAUSE MARKET, BY REGION ...... 79 10.1 OVERVIEW .......................... 79 10.2 NORTH AMERICA .................. 81 10.2.1 US ........................... 85 10.2.2 CANADA .................. 87 10.3 EUROPE ........................... 89 10.3.1 GERMANY ................ 93 10.3.2 UK ........................... 95 10.3.3 FRANCE ................... 97 10.3.4 NETHERLAND ........... 99 10.3.5 ITALY ....................... 101 10.3.6 SPAIN ...................... 103 10.3.7 REST OF EUROPE ...... 105 10.4 ASIA-PACIFIC ................... 107 10.4.1 CHINA ...................... 111 10.4.2 INDIA ....................... 113 10.4.3 JAPAN ..................... 115 10.4.4 SOUTH KOREA .......... 117 10.4.5 MALAYSIA ............... 119 10.4.6 THAILAND ................ 121 10.4.7 INDONESIA .............. 123 10.4.8 REST OF ASIA-PACIFIC ........................................ 125 10.5 LATIN AMERICA ............... 127 10.5.1 BRAZIL ..................... 131 10.5.2 MEXICO ................... 133 10.5.3 ARGENTINA ............. 135 10.5.4 REST OF LATIN AMERICA ..................................... 137 10.6 MIDDLE EAST AND AFRICA ...... 139 10.6.1 GCC COUNTRIES ...... 143 10.6.2 SOUTH AFRICA ......... 145 10.6.3 REST OF MIDDLE EAST AND AFRICA .................... 147 11 COMPETITIVE LANDSCAPE ................................... 151 11.1 INTRODUCTION ..................... 151 11.2 MARKET SHARE ANALYSIS, 2025 ........................................ 151 11.3 COMPETITOR DASHBOARD ....... 152 11.4 PUBLIC PLAYERS STOCK SUMMARY ..................................... 153 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ................. 153 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ............. 154 11.6.1 PRODUCT LAUNCH .............................................. 154 11.6.2 REGULATORY APPROVAL .................................... 154 11.6.3 CLINICAL STUDY ...... 154 11.6.4 PRODUCT APPROVAL .......................................... 155 12 COMPANY PROFILES ............................................. 156 12.1 BAYER AG .......................... 156 12.1.1 COMPANY OVERVIEW .......................................... 156 12.1.2 FINANCIAL OVERVIEW ......................................... 157 12.1.3 PRODUCTS OFFERED ........................................... 158 12.1.4 KEY DEVELOPMENTS .......................................... 158 12.1.5 SWOT ANALYSIS ...... 159 12.1.6 KEY STRATEGIES ...... 159 12.2 PFIZER INC. ........................ 160 12.2.1 COMPANY OVERVIEW .......................................... 160 12.2.2 FINANCIAL OVERVIEW ......................................... 161 12.2.3 PRODUCTS OFFERED ........................................... 162 12.2.4 KEY DEVELOPMENTS .......................................... 162 12.2.5 SWOT ANALYSIS ...... 162 12.2.6 KEY STRATEGIES ...... 163 12.3 SANDOZ GROUP AG ............. 164 12.3.1 COMPANY OVERVIEW .......................................... 164 12.3.2 FINANCIAL OVERVIEW ......................................... 165 12.3.3 PRODUCTS OFFERED ........................................... 166 12.3.4 KEY DEVELOPMENTS .......................................... 166 12.3.5 KEY STRATEGIES ...... 166 12.4 ABBVIE INC........................ 167 12.4.1 COMPANY OVERVIEW .......................................... 167 12.4.2 FINANCIAL OVERVIEW ......................................... 168 12.4.3 PRODUCTS OFFERED ........................................... 169 12.4.4 KEY DEVELOPMENTS .......................................... 169 12.4.5 SWOT ANALYSIS ...... 169 12.4.6 KEY STRATEGIES ...... 170 12.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. ............................. 171 12.5.1 COMPANY OVERVIEW .......................................... 171 12.5.2 FINANCIAL OVERVIEW ......................................... 172 12.5.3 PRODUCTS OFFERED ........................................... 173 12.5.4 KEY DEVELOPMENTS .......................................... 173 12.5.5 KEY STRATEGIES ...... 173 12.6 THERAMEX ......................... 174 12.6.1 COMPANY OVERVIEW .......................................... 174 OVERALL, THERAMEX MAINTAINS A STRONG POSITION AS A SPECIALIZED MANUFACTURER WITH PRESENCE ACROSS ALL MAJOR SEGMENTS OF THE WOMEN’S HEALTH PHARMACEUTICAL MARKET, FOCUSING ON TARGETED THERAPEUTIC SOLUTIONS AND LIFECYCLE MANAGEMENT. ......................... 174 12.6.2 FINANCIAL OVERVIEW ......................................... 174 12.6.3 PRODUCTS OFFERED ........................................... 175 12.6.4 KEY DEVELOPMENTS .......................................... 175 12.6.5 KEY STRATEGIES ...... 175 12.7 BESINS HEALTHCARE ............ 176 12.7.1 COMPANY OVERVIEW .......................................... 176 12.7.2 FINANCIAL OVERVIEW ......................................... 177 12.7.3 PRODUCTS OFFERED ........................................... 177 12.7.4 KEY DEVELOPMENTS .......................................... 177 12.7.5 KEY STRATEGIES ...... 177 12.8 ASTELLAS PHARMA INC. ......... 178 12.8.1 COMPANY OVERVIEW .......................................... 178 12.8.2 FINANCIAL OVERVIEW ......................................... 179 12.8.3 PRODUCTS OFFERED ........................................... 179 12.8.4 KEY DEVELOPMENTS .......................................... 180 12.8.5 KEY STRATEGIES ...... 180 12.9 AMGEN INC. ....................... 181 12.9.1 COMPANY OVERVIEW .......................................... 181 12.9.2 FINANCIAL OVERVIEW ......................................... 182 12.9.3 PRODUCTS OFFERED ........................................... 182 12.9.4 KEY DEVELOPMENTS .......................................... 183 12.9.5 SWOT ANALYSIS ...... 183 12.9.6 KEY STRATEGIES ...... 184 12.10 NOVARTIS AG .................. 185 12.10.1 COMPANY OVERVIEW .......................................... 185 12.10.2 FINANCIAL OVERVIEW ......................................... 186 12.10.3 PRODUCTS OFFERED ........................................... 187 12.10.4 KEY DEVELOPMENTS .......................................... 187 12.10.5 SWOT ANALYSIS ...... 187 12.10.6 KEY STRATEGIES ...... 188 12.11 DATA CITATIONS .................. 189
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 37 TABLE 2 NORTH AMERICA PRICING ANALYSIS, BY PRODUCT 52 TABLE 3 EUROPE PRICING ANALYSIS, BY PRODUCT 52 TABLE 4 ASIA PACIFIC PRICING ANALYSIS, BY PRODUCT 52 TABLE 5 REST OF THE WORLD PRICING ANALYSIS, BY PRODUCT 52 TABLE 6 PRODUCT PIPELINE 61 TABLE 7 GLOBAL MENOPAUSE MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 69 TABLE 8 GLOBAL MENOPAUSE MARKET, BY HORMONAL TYPE, 2019-2035 (USD MILLION) 69 TABLE 9 GLOBAL MENOPAUSE MARKET, BY HORMONAL TYPE, 2019-2035 (USD MILLION) 70 TABLE 10 GLOBAL MENOPAUSE MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION) 72 TABLE 11 GLOBAL MENOPAUSE MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 74 TABLE 12 GLOBAL MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 77 TABLE 13 GLOBAL MENOPAUSE MARKET, BY REGION, 2019-2035 (USD MILLION) 79 TABLE 14 NORTH AMERICA MENOPAUSE MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 82 TABLE 15 NORTH AMERICA MENOPAUSE MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 83 TABLE 16 NORTH AMERICA MARKET, BY HORMONAL TYPE, 2019-2035 (USD MILLION) 83 TABLE 17 NORTH AMERICA MENOPAUSE MARKET, BY HORMONAL TYPE, 2019-2035 (USD MILLION) 83 TABLE 18 NORTH AMERICA MENOPAUSE MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION) 84 TABLE 19 NORTH AMERICA MENOPAUSE MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 84 TABLE 20 NORTH AMERICA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 84 TABLE 21 US MENOPAUSE MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 85 TABLE 22 US MENOPAUSE MARKET, BY HORMONAL TYPE, 2019-2035 (USD MILLION) 85 TABLE 23 US MENOPAUSE MARKET, BY HORMONAL TYPE, 2019-2035 (USD MILLION) 85 TABLE 24 US MENOPAUSE MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION) 86 TABLE 25 US MENOPAUSE MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 86 TABLE 26 US MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 86 TABLE 27 CANADA MENOPAUSE MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 87 TABLE 28 CANADA MENOPAUSE MARKET, BY HORMONAL TYPE, 2019-2035 (USD MILLION) 87 TABLE 29 CANADA MENOPAUSE MARKET, BY HORMONAL TYPE, 2019-2035 (USD MILLION) 87 TABLE 30 CANADA MENOPAUSE MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION) 88 TABLE 31 CANADA MENOPAUSE MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 88 TABLE 32 CANADA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 88 TABLE 33 EUROPE MENOPAUSE MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 90 TABLE 34 EUROPE MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 91 TABLE 35 EUROPE MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 91 TABLE 36 EUROPE MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 91 TABLE 37 EUROPE MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 92 TABLE 38 EUROPE MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 92 TABLE 39 EUROPE MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 92 TABLE 40 GERMANY MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 93 TABLE 41 GERMANY MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 93 TABLE 42 GERMANY MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 93 TABLE 43 GERMANY MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 94 TABLE 44 GERMANY MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 94 TABLE 45 GERMANY MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 94 TABLE 46 UK MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 95 TABLE 47 UK MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 95 TABLE 48 UK MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 95 TABLE 49 UK MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 96 TABLE 50 UK MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 96 TABLE 51 UK MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 96 TABLE 52 FRANCE MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 97 TABLE 53 FRANCE MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 97 TABLE 54 FRANCE MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 97 TABLE 55 FRANCE MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 98 TABLE 56 FRANCE MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 98 TABLE 57 FRANCE MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 98 TABLE 58 NETHERLAND MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 99 TABLE 59 NETHERLAND MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 99 TABLE 60 NETHERLAND MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 99 TABLE 61 NETHERLAND MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 100 TABLE 62 NETHERLAND MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 100 TABLE 63 NETHERLAND MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 100 TABLE 64 ITALY MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 101 TABLE 65 ITALY MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 101 TABLE 66 ITALY MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 101 TABLE 67 ITALY MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 102 TABLE 68 ITALY MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 102 TABLE 69 ITALY MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 102 TABLE 70 SPAIN MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 103 TABLE 71 SPAIN MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 103 TABLE 72 SPAIN MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 103 TABLE 73 SPAIN MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 104 TABLE 74 SPAIN MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 104 TABLE 75 SPAIN MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 104 TABLE 76 REST OF EUROPE MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 105 TABLE 77 REST OF EUROPE MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 105 TABLE 78 REST OF EUROPE MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 105 TABLE 79 REST OF EUROPE MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 106 TABLE 80 REST OF EUROPE MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 106 TABLE 81 REST OF EUROPE MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 106 TABLE 82 ASIA-PACIFIC MENOPAUSE MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 108 TABLE 83 ASIA-PACIFIC MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 109 TABLE 84 ASIA-PACIFIC MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 109 TABLE 85 ASIA-PACIFIC MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 109 TABLE 86 ASIA-PACIFIC MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 110 TABLE 87 ASIA-PACIFIC MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 110 TABLE 88 ASIA-PACIFIC MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 110 TABLE 89 CHINA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 111 TABLE 90 CHINA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 111 TABLE 91 CHINA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 111 TABLE 92 CHINA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 112 TABLE 93 CHINA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 112 TABLE 94 CHINA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 112 TABLE 95 INDIA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 113 TABLE 96 INDIA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 113 TABLE 97 INDIA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 113 TABLE 98 INDIA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 114 TABLE 99 INDIA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 114 TABLE 100 INDIA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 114 TABLE 101 JAPAN MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 115 TABLE 102 JAPAN MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 115 TABLE 103 JAPAN MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 115 TABLE 104 JAPAN MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 116 TABLE 105 JAPAN MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 116 TABLE 106 JAPAN MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 116 TABLE 107 SOUTH KOREA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 117 TABLE 108 SOUTH KOREA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 117 TABLE 109 SOUTH KOREA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 117 TABLE 110 SOUTH KOREA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 118 TABLE 111 SOUTH KOREA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 118 TABLE 112 SOUTH KOREA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 118 TABLE 113 MALAYSIA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 119 TABLE 114 MALAYSIA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 119 TABLE 115 MALAYSIA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 119 TABLE 116 MALAYSIA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 120 TABLE 117 MALAYSIA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 120 TABLE 118 MALAYSIA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 120 TABLE 119 THAILAND MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 121 TABLE 120 THAILAND MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 121 TABLE 121 THAILAND MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 121 TABLE 122 THAILAND MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 122 TABLE 123 THAILAND MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 122 TABLE 124 THAILAND MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 122 TABLE 125 INDONESIA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 123 TABLE 126 INDONESIA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 123 TABLE 127 INDONESIA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 123 TABLE 128 INDONESIA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 124 TABLE 129 INDONESIA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 124 TABLE 130 INDONESIA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 124 TABLE 131 REST OF ASIA-PACIFIC MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 125 TABLE 132 REST OF ASIA-PACIFIC MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 125 TABLE 133 REST OF ASIA-PACIFIC MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 125 TABLE 134 REST OF ASIA-PACIFIC MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 126 TABLE 135 REST OF ASIA-PACIFIC MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 126 TABLE 136 REST OF ASIA-PACIFIC MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 126 TABLE 137 LATIN AMERICA MENOPAUSE MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 128 TABLE 138 LATIN AMERICA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 128 TABLE 139 LATIN AMERICA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 129 TABLE 140 LATIN AMERICA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 129 TABLE 141 LATIN AMERICA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 129 TABLE 142 LATIN AMERICA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 130 TABLE 143 LATIN AMERICA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 130 TABLE 144 BRAZIL MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 131 TABLE 145 BRAZIL MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 131 TABLE 146 BRAZIL MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 131 TABLE 147 BRAZIL MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 132 TABLE 148 BRAZIL MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 132 TABLE 149 BRAZIL MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 132 TABLE 150 MEXICO MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 133 TABLE 151 MEXICO MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 133 TABLE 152 MEXICO MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 133 TABLE 153 MEXICO MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 134 TABLE 154 MEXICO MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 134 TABLE 155 MEXICO MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 134 TABLE 156 ARGENTINA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 135 TABLE 157 ARGENTINA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 135 TABLE 158 ARGENTINA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 135 TABLE 159 ARGENTINA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 136 TABLE 160 ARGENTINA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 136 TABLE 161 ARGENTINA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 136 TABLE 162 REST OF LATIN AMERICA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 137 TABLE 163 REST OF LATIN AMERICA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 137 TABLE 164 REST OF LATIN AMERICA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 137 TABLE 165 REST OF LATIN AMERICA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 138 TABLE 166 REST OF LATIN AMERICA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 138 TABLE 167 REST OF LATIN AMERICA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 138 TABLE 168 MIDDLE EAST AND AFRICA MENOPAUSE MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 140 TABLE 169 MIDDLE EAST AND AFRICA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 140 TABLE 170 MIDDLE EAST AND AFRICA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 141 TABLE 171 MIDDLE EAST AND AFRICA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 141 TABLE 172 MIDDLE EAST AND AFRICA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 141 TABLE 173 MIDDLE EAST AND AFRICA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 142 TABLE 174 MIDDLE EAST AND AFRICA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 142 TABLE 175 GCC COUNTRIES MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 143 TABLE 176 GCC COUNTRIES MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 143 TABLE 177 GCC COUNTRIES MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 143 TABLE 178 GCC COUNTRIES MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 144 TABLE 179 GCC COUNTRIES MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 144 TABLE 180 GCC COUNTRIES MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 144 TABLE 181 SOUTH AFRICA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 145 TABLE 182 SOUTH AFRICA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 145 TABLE 183 SOUTH AFRICA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 145 TABLE 184 SOUTH AFRICA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 146 TABLE 185 SOUTH AFRICA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 146 TABLE 186 SOUTH AFRICA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 146 TABLE 187 REST OF MIDDLE EAST AND AFRICA MENOPAUSE MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 147 TABLE 188 REST OF MIDDLE EAST AND AFRICA MENOPAUSE MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION) 147 TABLE 189 REST OF MIDDLE EAST AND AFRICA MENOPAUSE MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION) 147 TABLE 190 REST OF MIDDLE EAST AND AFRICA MENOPAUSE MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION) 148 TABLE 191 REST OF MIDDLE EAST AND AFRICA MENOPAUSE MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 148 TABLE 192 REST OF MIDDLE EAST AND AFRICA MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 149 TABLE 193 PRODUCT LAUNCH 154 TABLE 194 REGULATORY APPROVAL 154 TABLE 195 CLINICAL STUDY 154 TABLE 196 PRODUCT APPROVAL 155 TABLE 197 BAYER AG: PRODUCT OFFERED 158 TABLE 198 BAYER AG: KEY DEVELOPMENTS 158 TABLE 199 PFIZER INC.: PRODUCTS OFFERED 162 TABLE 200 SANDOZ GROUP AG: PRODUCT OFFERED 166 TABLE 201 ABBVIE, INC.: PRODUCTS OFFERED 169 TABLE 202 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED 173 TABLE 203 THERAMEX: PRODUCTS OFFERED 175 TABLE 204 THERAMEX: KEY DEVELOPMENTS 175 TABLE 205 BESINS HEALTHCARE: PRODUCTS OFFERED 177 TABLE 206 ASTELLAS PHARMA INC.: PRODUCTS OFFERED 179 TABLE 207 ASTELLAS PHARMA INC.: KEY DEVELOPMENTS 180 TABLE 208 AMGEN INC.: PRODUCTS OFFERED 182 TABLE 209 AMGEN INC.: KEY DEVELOPMENTS 183 TABLE 210 NOVARTIS AG: PRODUCTS OFFERED 187 LIST OF FIGURES FIGURE 1 GLOBAL MENOPAUSE MARKET: STRUCTURE 23 FIGURE 2 GLOBAL MENOPAUSE MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2035) 40 FIGURE 3 GLOBAL MENOPAUSE MARKET DRIVER: IMPACT ANALYSIS 43 FIGURE 4 GLOBAL MENOPAUSE MARKET RESTRAINT: IMPACT ANALYSIS 46 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL MENOPAUSE MARKET 59 FIGURE 6 GLOBAL MENOPAUSE MARKET, TREATMENT SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 68 FIGURE 7 GLOBAL MENOPAUSE MARKET, BY TREATMENT, 2025 & 2035 (USD MILLION) 69 FIGURE 8 GLOBAL MENOPAUSE MARKET SHARE (%), BY TREATMENT, 2025 70 FIGURE 9 GLOBAL MENOPAUSE MARKET, MENOPAUSE STAGESEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 71 FIGURE 10 GLOBAL MENOPAUSE MARKET, BY MENOPAUSE STAGE, 2025 & 2035 (USD MILLION) 71 FIGURE 11 GLOBAL MENOPAUSE MARKET SHARE (%), BY MENOPAUSE STAGE, 2025 72 FIGURE 12 GLOBAL MENOPAUSE MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 73 FIGURE 13 GLOBAL MENOPAUSE MARKET, BY APPLICATION, 2025 & 2035 (USD MILLION) 74 FIGURE 14 GLOBAL MENOPAUSE MARKET SHARE (%), BY APPLICATION, 2025 75 FIGURE 15 GLOBAL MENOPAUSE MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 76 FIGURE 16 GLOBAL MENOPAUSE MARKET, BY DISTRIBUTION CHANNEL, 2025 & 2035 (USD MILLION) 77 FIGURE 17 GLOBAL MENOPAUSE MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2025 78 FIGURE 18 GLOBAL MENOPAUSE MARKET, BY REGION, 2025 & 2035 (USD MILLION) 79 FIGURE 19 GLOBAL MENOPAUSE MARKET SHARE (%), BY REGION, 2025 80 FIGURE 20 NORTH AMERICA MARKET ANALYSIS: MENOPAUSE MARKET, 2019-2035 (USD MILLION) 81 FIGURE 21 NORTH AMERICA MENOPAUSE MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 81 FIGURE 22 NORTH AMERICA MENOPAUSE MARKET SHARE (%), BY COUNTRY, 2025 82 FIGURE 23 EUROPE ANALYSIS: MENOPAUSE MARKET, 2019-2035 (USD MILLION) 89 FIGURE 24 EUROPE MENOPAUSE MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 89 FIGURE 25 EUROPE MENOPAUSE MARKET, BY COUNTRY, 2025 (USD MILLION) 90 FIGURE 26 ASIA PACIFIC ANALYSIS: MENOPAUSE MARKET, 2019-2035 (USD MILLION) 107 FIGURE 27 ASIA-PACIFIC MENOPAUSE MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 107 FIGURE 28 ASIA PACIFIC MENOPAUSE MARKET, BY COUNTRY, 2025 (USD MILLION) 108 FIGURE 29 LATIN AMERICA ANALYSIS: MENOPAUSE MARKET, 2019-2035 (USD MILLION) 127 FIGURE 30 LATIN AMERICA MENOPAUSE MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 127 FIGURE 31 LATIN AMERICA MENOPAUSE MARKET, BY COUNTRY, 2025 (USD MILLION) 128 FIGURE 32 MIDDLE EAST AND AFRICA ANALYSIS: MENOPAUSE MARKET, 2019-2035 (USD MILLION) 139 FIGURE 33 MIDDLE EAST AND AFRICA MENOPAUSE MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 139 FIGURE 34 MIDDLE EAST AND AFRICA MENOPAUSE MARKET, BY COUNTRY, 2025 (USD MILLION) 140 FIGURE 35 GLOBAL MENOPAUSE MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 151 FIGURE 36 COMPETITOR DASHBOARD: GLOBAL MENOPAUSE MARKET 152 FIGURE 37 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 157 FIGURE 38 BAYER AG : SWOT ANALYSIS 159 FIGURE 39 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 161 FIGURE 40 PFIZER INC.: SWOT ANALYSIS 162 FIGURE 41 SANDOZ GROUP AG: FINANCIAL OVERVIEW SNAPSHOT 165 FIGURE 42 ABBVIE, INC.: FINANCIAL OVERVIEW SNAPSHOT 168 FIGURE 43 ABBVIE, INC.: SWOT ANALYSIS 169 FIGURE 44 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 172 FIGURE 45 ASTELLAS PHARMA INC.: FINANCIAL OVERVIEW SNAPSHOT 179 FIGURE 46 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 182 FIGURE 47 AMGEN INC.: SWOT ANALYSIS 183 FIGURE 48 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 186 FIGURE 49 NOVARTIS AG: SWOT ANALYSIS 187

提及公司

TheramexBesins HealthcareAstellas Pharma Inc.Amgen Inc.Novartis AGBayer AGPfizer Inc.Sandoz Group AGAbbVieInc.Teva Pharmaceutical Industries Ltd.

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們